Guillain-Barre syndrome is a rare but serious condition which needs urgent treatment in hospital to prevent it progressing.

The UK's medicines regulator has warned NHS healthcare staff about an increased risk of a condition affecting the nerves in ...

GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

Arexvy was the first vaccine approved to prevent respiratory syncytial virus (RSV). RSV is a common virus that usually causes mild cold-like symptoms. These symptoms can be more severe in babies ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Researchers found that older adults who received AS01-adjuvanted shingles or RSV vaccines had a significantly lower risk of ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

Arexvy dominates U.S. retail vaccine market in Q3; management optimistic but mindful of competitive landscape. Investment recommendation: "Speculative Buy" on GSK, ...

Arexvy, which is used to prevent lower respiratory tract infections, can cause side effects. Learn about its more common, mild, and serious side effects and how to manage them.

Arexvy is a vaccine used to prevent certain infections caused by the respiratory syncytial virus (RSV). Learn about cost, how to find savings, and more.

Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known ...